Aquestive Therapeutics
AQST
63 hedge funds and large institutions have $86.3M invested in Aquestive Therapeutics in 2021 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 18 increasing their positions, 21 reducing their positions, and 15 closing their positions.
3% less funds holding
Funds holding: 65 → 63 (-2)
11.02% less ownership
Funds ownership: 56.93% → 45.91% (-11%)
13% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 15
14% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 21
16% less capital invested
Capital invested by funds: $102M → $86.3M (-$16M)
23% less call options, than puts
Call options by funds: $902K | Put options by funds: $1.17M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.72M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$1.24M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.1M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$736K |
| 5 |
IA
IndexIQ Advisors
New York
|
+$476K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bratton Capital Management
Fort Worth,
Texas
|
-$9M |
| 2 |
PA
Perceptive Advisors
New York
|
-$7.41M |
| 3 |
Renaissance Technologies
New York
|
-$1.45M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$1.12M |
| 5 |
Nisa Investment Advisors
St. Louis,
Missouri
|
-$348K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
QT
76
Quantbot Technologies
New York
| – | -$14K | -2,783 | Closed |
|
77
Fidelity Investments
Boston,
Massachusetts
| – | -$2K | -400 | Closed |
|
|
HI
78
Harbour Investments
Madison,
Wisconsin
| – | +$399 | +75 | New |
|
AQST Hedge Fund Activity: Q1 2021 in Review
63 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q1 2021, worth a combined $86.3M — down 16% from $102M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of AQST and 13 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 18 added.
The largest buyer was Morgan Stanley, adding an estimated $1.72M. The largest seller was Bratton Capital Management, cutting an estimated $9M.
- 63 institutional investors held Aquestive Therapeutics (AQST) as of Q1 2021, down from 65 in Q4 2020.
- Funds reported $86.3M of Aquestive Therapeutics stock for Q1 2021, down 16% quarter-over-quarter.
- 13 funds opened new Aquestive Therapeutics positions in Q1 2021 and 15 closed out, a net change of -2 holders.
- The largest Aquestive Therapeutics buyer in Q1 2021 was Morgan Stanley, an estimated $1.72M added.
- The largest Aquestive Therapeutics seller in Q1 2021 was Bratton Capital Management, an estimated $9M sold.
Based on aggregated 13F filings for Q1 2021.